NFKB1 and hepatocellular carcinoma: GAR has previously shown to have reduced inflammatory markers like TNF-α and NF-κB in hepatic inflammation in the steatohepatitis-derived hepatocellular carcinoma of a mouse model (STAM) and LPS-induced inflammation in THP-1 cells in vitro [50].